Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ennio Favalli"'
Autor:
Andreina Manfredi, Marco Sebastiani, Florenzo Iannone, Elisa Gremese, Alessandra Bortoluzzi, Ennio Favalli, Roberto Gorla, Fausto Salaffi, Enrico Fusaro, Rosario Foti, Luca Cantarini, Roberto Caporali, Alberto Cauli, Stefano Alivernini, Francesco Paolo Cantatore, Antonio Carletto, Fabrizio Conti, Salvatore D'Angelo, Oscar Epis, Roberta Ramonda, Antonio Marchesoni, Gianfranco Ferraccioli, Giovanni Lapadula
Publikováno v:
Indian Journal of Rheumatology, Vol 14, Iss 4, Pp 271-276 (2019)
Objective: Despite the well-established efficacy of methotrexate (MTX) in rheumatoid arthritis (RA), monotherapy is not sufficient in almost half of patients. The aim of this registry-based study was to detect possible predictive factors for the earl
Externí odkaz:
https://doaj.org/article/db97b3d688364b4b8c4ce9664195412a
Autor:
Maya H Buch, Gerd R Burmester, Xavier Mariette, Christina Charles-Schoeman, Vijay Rajendran, Pieter-Jan Stiers, Agustin Cerani, Paul Van Hoek, Katrien Van Beneden, Yoshiya Tanaka, Hendrik Schulze-Koops, René Westhovens, Ennio Favalli
Publikováno v:
Rheumatology. 62
Background/Aims The safety profile of filgotinib (FIL), a second-generation oral Janus kinase (JAK) 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment of rheumatoid arthritis (RA) has been reported. In patients (pts) with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce527194fe5dca05cc9f9829e6bfb6b
https://doi.org/10.1093/rheumatology/kead104.152
https://doi.org/10.1093/rheumatology/kead104.152
Autor:
Marco, Sebastiani, Vincenzo, Venerito, Serena, Bugatti, Chiara, Bazzani, Martina, Biggioggero, Luca, Petricca, Rosario, Foti, Alessandra, Bortoluzzi, Silvia, Balduzzi, Elisa, Visalli, Bruno, Frediani, Andreina, Manfredi, Elisa, Gremese, Ennio, Favalli, Florenzo, Iannone, Gianfranco, Ferraccioli, Giovanni, Lapadula, Giuseppe, Lopalco
EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug (bDMARD) should be preferred after failure of a first bDMARD in the treatment of rheumatoid arthritis (RA). In particular, few data are available regarding the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0598ce95ae9b196293d96d825fc439
https://hdl.handle.net/11392/2470557
https://hdl.handle.net/11392/2470557
Autor:
FRANCESCA INGEGNOLI, tania ubiali, tommaso schioppo, valentina longo, Antonella Murgo, orazio de lucia, ennio favalli, simona iodice, valentina bollati, roberto caporali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1accdb153695e57f3d0820c874c7c96
https://doi.org/10.22541/au.160491841.12640782/v1
https://doi.org/10.22541/au.160491841.12640782/v1
Autor:
Alvin, Yee, Tyler, Webb, Andrea, Seaman, Maria, Infantino, Francesca, Meacci, Mariangela, Manfredi, Maurizio, Benucci, Gabriella, Lakos, Ennio, Favalli, Tommaso, Schioppo, Tommaso, Shioppo, Pier-Luigi, Meroni, Michael, Mahler
Publikováno v:
Immunologic research. 61(1-2)
Anti-citrullinated protein antibodies (ACPA) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the recent disease classification criteria. However, there is a strong need for reliable markers for measurin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad37f19313d87811cf0cb58cd0a0dc19
https://pubmed.ncbi.nlm.nih.gov/25796173
https://pubmed.ncbi.nlm.nih.gov/25796173